A retrospective analysis of real-world outcomes of elderly Chinese patients with diffuse large B-cell lymphoma
| Autor: | Peng Liu, Ying Han, Shi-Yu Jiang, Xiao-Hui He, Yan Qin, Lin Gui, Sheng-Yu Zhou, Li-Qiang Zhou, Jian- Liang Yang, Sheng Yang, Ting-Yu Wen, Yuan-Kai Shi, Peng Lyu |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2019 |
| Předmět: |
Oncology
medicine.medical_specialty MEDLINE lcsh:Medicine 03 medical and health sciences 0302 clinical medicine Text mining Antineoplastic Agents Immunological Elderly immune system diseases hemic and lymphatic diseases Internal medicine medicine Retrospective analysis Humans Progression-free survival Cyclophosphamide Aged Retrospective Studies L-Lactate Dehydrogenase business.industry lcsh:R Real world outcomes Retrospective cohort study social sciences General Medicine Original Articles Diffuse large B-cell lymphoma Middle Aged medicine.disease Prognosis humanities Progression-Free Survival Lymphoma body regions Doxorubicin Vincristine 030220 oncology & carcinogenesis Prednisone Lymphoma Large B-Cell Diffuse business Rituximab 030217 neurology & neurosurgery |
| Zdroj: | Chinese Medical Journal, Vol 132, Iss 15, Pp 1807-1814 (2019) Chinese Medical Journal |
| ISSN: | 2542-5641 0366-6999 |
| Popis: | Background:. Elderly patients with diffuse large B-cell lymphoma (DLBCL) have a worse prognosis than younger patients, and the optimal treatment strategy for this group remains controversial. We conducted a retrospective analysis to investigate the clinical features and outcomes of elderly patients (>60 years) and to assess the impact of clinical and molecular factors on outcome in this age group. Methods:. From April 2006 to December 2012, a total of 349 elderly patients with DLBCL from the National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences, and Peking Union Medical College were included in this analysis. Patients were further divided into two age groups (61–69 years and ≥70 years). We compared clinical characteristics and outcomes between groups. Results:. Of 349 total patients, 204 (58.5%) were aged 61 to 69 years, and 145 (41.5%) patients were aged 70 years or older. Except for the Eastern Cooperative Oncology Group performance status, clinical characteristics were comparable between the two groups. With a median follow-up of 82 (range, 1–129) months, the 5-year overall survival (OS) and progression-free survival (PFS) rates were 51.9% and 45.8%, respectively. The 5-year OS rates for patients aged 61 to 69 years and those over 70 years were 58.3% and 42.8% (P = 0.007), respectively, and the 5-year PFS rates were 51.0% and 38.6% (P = 0.034). Treatment regimens including rituximab provided a higher 5-year OS rate (63.1% vs. 37.1%, P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|